RMAT list

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

Cool Cat iPS cells & other notable stem cell pubs/news

Gur-Cohen-et-al.-Science-Figure-2b

Once or twice a month I do a post on notable stem cell publications and news, which often but not always include research on iPS cells. It’s sort of a recommended reads kind of post, but I often include one or two things that aren’t necessarily recommended exactly yet seem kind of surprising or novel …

Cool Cat iPS cells & other notable stem cell pubs/news Read More »

Stem cell news July 2018: RMATs, RTT, MiMedx mess, clinic family ties & more

Bob-Comella-U.S.-Stem-

The year of 2018 has already been a wild one for stem cell news. There are many developments on a variety of fronts. Here are some of the most notable news bites of the last month or so. RMAT Wave. The FDA continues its warp-speed issuance of Regenerative Medicine Advanced Therapy (RMAT) designations with 20 …

Stem cell news July 2018: RMATs, RTT, MiMedx mess, clinic family ties & more Read More »

Japan stem cell oversight system too lax?

HeartSheet-Japan-system-stem-cell-oversight

The Japan stem cell and regenerative medicine oversight system has been designed to move investigational therapies forward fast, much faster than the systems in other countries such as the U.S. But how well is it working so far? It’s an important question both for that country and more globally as the Japanese system was touted …

Japan stem cell oversight system too lax? Read More »